High-cost drugs remain the primary cost driver for Canadian public and private drug plans, said the Patented Medicine Prices Review Board’s newly released 2019 annual report. Patty Hajdu, the federal government’s minister of health, tabled the report, which found the sales of patented drugs grew 3.5 per cent to over $17 billion in 2019. Additionally, […]
The Ontario Securities Commission has laid out its priorities for 2019-20, which focus on promoting confidence in Ontario’s capital markets and reducing regulatory burden. In terms of confidence building, the commission said it intends to continue consulting on client-focused reforms and on the Canadian Securities Administrators’ policy consultations on mutual fund embedded commissions; improve the […]
For marketable orders, we find that there is generally little difference across smart routers.
"It just may be that the suddenly electronic NYSE, stripped of its uptick rule, faced more efficiency than it could handle."